

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over ID6394

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
CSL Behring (garadacimab)	 All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Action for Children	Board of Community Health Councils in
Allergy UK	Wales
Anaphylaxis Campaign	British National Formulary
Asthma and Lung UK	Care Quality Commission
Genetic Alliance UK	Department of Health - Northern Ireland
HAE UK	Healthcare Improvement Scotland
Immunodeficiency UK	Hospital Information Services –
Jnetics	Jehovah's Witnesses
 NARA- The Breathing Charity 	Medicines and Healthcare products
 National Children's Bureau 	Regulatory Agency
 South Asian Health Foundation 	 National Association of Primary Care
Specialised Healthcare Alliance	 National Pharmacy Association NHS Confederation
Healthcare professional groups	 Scottish Medicines Consortium
Association for Respiratory	Welsh Government
Technology and Physiology	Welsh Health Specialised Services
Association of Genetic Nurses &	Committee
Counsellors	
Association of Paediatric Emergency	Possible comparator companies
Medicine	BioCryst Pharmaceuticals (berotralstat)
British Geriatrics Society	CSL Behring (Berinert)
British Paediatric Allergy, Immunity	Maxwellia (tranexamic acid)
and Infection Group (BPAIIG)	Mylan (tranexamic acid)
British Paediatric Respiratory Society	 Pharming Group N.V (Ruconest)
British Skin Foundation	 Rivopharm (tranexamic acid)
British Society for Allergy & Clinical	 Sovereign Medical (tranexamic acid)
Immunology	 Takeda (Cinryze, lanadelumab)
British Society for Genetic Medicine	 Tillomed Laboratories (tranexamic acid)
British Society for Haematology	
British Society for Immunology	Relevant research groups
British Thoracic Society	 Asthma, Allergy and Inflammation
,	Research Trust

Provisional stakeholder list for the evaluation of garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over ID6394 Issue date: June 2024

© National Institute for Health and Care Excellence 2024. All rights reserved.

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 ILD-IN: Interstitial Lung Diseases Interdisciplinary Network Immunology and Allergy Nurses Group National Heart and Lung Institute Neonatal and Paediatric Pharmacists Group Primary Care Respiratory Society UK Royal College of General Practitioners Royal College of Paediatrics & Child Health Royal College of Paediatrics & Child Health Royal College of Physicians Royal College of Physicians Royal College of Medicine Royal Society of Medicine Royal Society of Medicine - Allergy and Immunology Section UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders <u>Others</u> Department of Health and Social Care NHS England 	 British Association for Lung Research Cochrane Airways Group David Hide Asthma and Allergy Research Centre Genomics England MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over ID6394 Issue date: June 2024 © National Institute for Health and Care Excellence 2024. All rights reserved. 2 of 3



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.